Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.
2.

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L.

Ann Oncol. 2007 Feb;18(2):226-32. Epub 2006 Nov 20. Review.

PMID:
17116643
3.

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.

Jinushi M, Hodi FS, Dranoff G.

Immunol Rev. 2008 Apr;222:287-98. doi: 10.1111/j.1600-065X.2008.00618.x. Review.

PMID:
18364009
4.

GM-CSF-based cancer vaccines.

Dranoff G.

Immunol Rev. 2002 Oct;188:147-54. Review.

PMID:
12445288
5.

Recent progress in GM-CSF-based cancer immunotherapy.

Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ.

Immunotherapy. 2017 Mar;9(4):347-360. doi: 10.2217/imt-2016-0141. Review.

PMID:
28303764
6.

Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Fernández A, Oliver L, Alvarez R, Fernández LE, Lee KP, Mesa C.

Hum Vaccin Immunother. 2014;10(11):3251-60. doi: 10.4161/hv.29847. Review.

7.

Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Yu TW, Chueh HY, Tsai CC, Lin CT, Qiu JT.

Hum Vaccin Immunother. 2016 Dec;12(12):3020-3028. doi: 10.1080/21645515.2016.1221551. Epub 2016 Aug 25. Review.

8.

GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.

Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS.

Cytokine. 2015 Oct;75(2):261-71. doi: 10.1016/j.cyto.2015.05.030. Epub 2015 Jun 22. Review.

9.

Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.

Hong IS.

Exp Mol Med. 2016 Jul 1;48(7):e242. doi: 10.1038/emm.2016.64. Review.

11.

Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man.

Mellstedt H, Fagerberg J, Osterborg A.

Eur J Cancer. 1999 Aug;35 Suppl 3:S29-32. Review. No abstract available.

PMID:
10645219
12.

GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation.

Becher B, Tugues S, Greter M.

Immunity. 2016 Nov 15;45(5):963-973. doi: 10.1016/j.immuni.2016.10.026. Review.

13.

Combination of GM-CSF with antitumour vaccine strategies.

Gaudernack G, Gjertsen MK.

Eur J Cancer. 1999 Aug;35 Suppl 3:S33-5. Review. No abstract available.

PMID:
10645220
14.

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Serafini P, Borrello I, Bronte V.

Semin Cancer Biol. 2006 Feb;16(1):53-65. Epub 2005 Sep 15. Review.

PMID:
16168663
15.

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells.

Maenhout SK, Thielemans K, Aerts JL.

Oncoimmunology. 2014 Dec 15;3(10):e956579. eCollection 2014 Nov. Review.

16.

Cytokine-mediated gene therapy for cancer.

Miller AR, McBride WH, Hunt K, Economou JS.

Ann Surg Oncol. 1994 Sep;1(5):436-50. Review.

PMID:
7850546
17.

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Wu AA, Drake V, Huang HS, Chiu S, Zheng L.

Oncoimmunology. 2015 Apr 1;4(7):e1016700. eCollection 2015 Jul. Review.

18.

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.

Hughes T, Coffin RS, Lilley CE, Ponce R, Kaufman HL.

Oncolytic Virother. 2014 Jan 15;3:11-20. doi: 10.2147/OV.S36701. eCollection 2014. Review.

19.

Clinical Development of the E75 Vaccine in Breast Cancer.

Clifton GT, Gall V, Peoples GE, Mittendorf EA.

Breast Care (Basel). 2016 Apr;11(2):116-21. doi: 10.1159/000446097. Epub 2016 Apr 26. Review.

20.

Advances in the understanding and treatment of sepsis-induced immunosuppression.

Venet F, Monneret G.

Nat Rev Nephrol. 2018 Feb;14(2):121-137. doi: 10.1038/nrneph.2017.165. Epub 2017 Dec 11. Review.

PMID:
29225343

Supplemental Content

Support Center